Similarly, in the PERFECT trial (Intramyocardial Transplantation of Bone Marrow Stem Cells for Improvement of Post-Infarct Myocardial Regeneration in Addition to CABG Surgery), patients with ischemic cardiomyopathy received intramyocardial autologous CD133+bone marrow cells or placebo at coronary revascularization surgery. Patient without left ventricle functional improvement after revascularization, regardless of treatment, had lower preprocedural levels of CD133+, CD34+, CD117+ endothelial progenitor cells and thrombocytes, with increased erythropoetin and SH2B3 gene expression in peripheral blood. Responders to CD133+ cell therapy had lower levels of preprocedural vascular endothelial growth factor, erythropoetin, and CXCL10 (C-X-C motif chemokine 10). Using these biomarkers, preprocedural predictive accuracy for responders and nonresponders approximated 80%.